# US 2025/0049710 A1 · Aqueous formulations of a cardiac p2x receptor agonist and their use in treating medical disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049710 A1
- Document ID: US20250049710A1
- Status: Published application
- Kind: A1
- Application number: 18/778,671
- Filed: 2024-07-19
- Published: 2025-02-13
- Earliest claimed: 2023-07-21
- Assignees: Comovus Pharmaceuticals, Inc.
- Applicants: Comovus Pharmaceuticals, Inc.
- Inventors: Bruce T. Liang; Mingliu Lei; Hongjuan Xue; Yinan Han; Wenjie Song; Menghua Li
- Web page: https://patentgrep.com/patent/US20250049710A1

## CPC

- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides aqueous formulations containing a compound that stimulates cardiac P2X receptor activity, and methods for their use in stimulating cardiac P2X receptor activity and treating medical disorders, such as heart failure.

## Claims

### Claim 1

An aqueous formulation, comprising:
(a) from 0.25% (w/v) to 0.75% (w/v) of a compound of Formula I, wherein Formula I is represented by:
or a pharmaceutically acceptable salt thereof;
(b) from 0.01% (w/v) to 0.03% (w/v) of a chelating agent selected from ethylenediamine tetraacetic acid, a pharmaceutically acceptable salt of ethylenediamine tetraacetic acid, or a mixture thereof;
(c) from 10 mM to 30 mM of a buffer comprising citric acid and a pharmaceutically acceptable salt of citric acid;
(d) from 3.5% (w/v) to 11% (w/v) of a tonicity modifier; and
(e) at least 90% (w/v) water; and
having a pH in the range of 7.5 to 8.5.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the compound of Formula I is present in an amount of from 0.4% (w/v) to 0.6% (w/v).

### Claim 3 (depends on 1)

The formulation of claim 1, wherein the compound of Formula I is present in an amount of about 0.5% (w/v).

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The formulation of claim 1, wherein the compound of Formula I is an alkali metal or alkaline earth metal pharmaceutically acceptable salt of

### Claim 7 (depends on 1)

The formulation of claim 1, wherein the compound of Formula I is a sodium salt of

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The formulation of claim 1, wherein the formulation comprises about 0.02% (w/v) of a chelating agent selected from ethylenediamine tetraacetic acid, a pharmaceutically acceptable salt of ethylenediamine tetraacetic acid, or a mixture thereof.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The formulation of claim 1, wherein the formulation comprises about 20 mM of a buffer comprising citric acid and a pharmaceutically acceptable salt of citric acid.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The formulation of claim 1, wherein the formulation comprises about 6.9% (w/v) of a tonicity modifier.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The formulation of claim 1, wherein the tonicity modifier is a disaccharide.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The formulation of claim 1, wherein the formulation has a pH in the range of 7.8 to 8.2.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The formulation of claim 1, wherein the formulation comprises at least 91% water.

### Claim 25

An aqueous formulation, comprising:
(a) about 0.5% (w/v) of a compound of Formula I, wherein Formula I is represented by:
or a pharmaceutically acceptable salt thereof;
(b) about 0.02% (w/v) of a chelating agent selected from ethylenediamine tetraacetic acid, a pharmaceutically acceptable salt of ethylenediamine tetraacetic acid, or a mixture thereof,
(c) about 20 mM of a buffer comprising citric acid and a pharmaceutically acceptable salt of citric acid;
(d) about 6.9% (w/v) of a tonicity modifier; and
(e) at least 90% (w/v) water; and
having a pH of about 8.

### Claim 26

An aqueous formulation, comprising:
(a) about 0.5% (w/v) of a compound of Formula I, wherein Formula I is represented by:
or a pharmaceutically acceptable salt thereof;
(b) about 0.02% (w/v) of a chelating agent selected from ethylenediamine tetraacetic acid, a pharmaceutically acceptable salt of ethylenediamine tetraacetic acid, or a mixture thereof,
(c) about 20 mM of a buffer comprising citric acid and a pharmaceutically acceptable salt of citric acid;
(d) about 6.9% (w/v) sucrose; and
(e) at least 90% (w/v) water; and
having a pH of about 8.

### Claim 27 (depends on 26)

The formulation of claim 26, wherein the formulation comprises:
(a) 0.5% (w/v) of a compound of Formula I, wherein Formula I is represented by:
or a pharmaceutically acceptable salt thereof;
(b) 0.02% (w/v) of a chelating agent selected from ethylenediamine tetraacetic acid, a pharmaceutically acceptable salt of ethylenediamine tetraacetic acid, or a mixture thereof;
(c) 20 mM of a buffer comprising citric acid and a pharmaceutically acceptable salt of citric acid;
(d) 6.9% (w/v) sucrose; and
(e) at least 90% (w/v) water; and
having a pH of 8.

### Claim at position 28

28-57. (canceled)

### Claim 58 (depends on 25)

The formulation of claim 25, wherein the formulation has an osmolality in the range from about 270 mOsm/kg to about 330 mOsm/kg.

### Claim 59

(canceled)

### Claim 60 (depends on 25)

The formulation of claim 25, wherein less than 1% by weight of compound of Formula I degrades upon storage of the formulation at 25° C. for 4 weeks.

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65 (depends on 25)

The formulation of claim 25, wherein less than 0.5% by weight of compound of Formula I degrades upon storage of the formulation at 40° C. for 4 weeks.

### Claim 66 (depends on 25)

The formulation of claim 25, wherein the formulation contains less than 0.02% (w/v) of the following compound or a pharmaceutically acceptable salt thereof:

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71

(canceled)

### Claim 72 (depends on 1)

An aqueous injectable formulation, comprising a formulation of claim 1 and a diluent for intravenous administration.

### Claim 73 (depends on 1)

An aqueous injectable formulation produced by admixing a formulation of claim 1 and a diluent for intravenous administration.

### Claim 74 (depends on 1)

A method of preparing an aqueous injectable formulation, comprising admixing a formulation of claim 1 and a diluent for intravenous administration.

### Claim 75 (depends on 73)

A method for treating a cardiac disorder, comprising administering to a subject in need thereof a therapeutically effective amount of an aqueous injectable formulation of claim 73 to treat the cardiac disorder.

### Claim 76 (depends on 73)

A method for improving cardiac contractile performance in a subject, comprising administering to a subject in need thereof an effective amount of an aqueous injectable formulation of claim 73 to improve cardiac contractile performance.

### Claim 77 (depends on 73)

A method for improving cardiac function in a subject, comprising administering to a subject in need thereof an effective amount of an aqueous injectable formulation of claim 73 to improve cardiac function.

### Claim at position 49

78-84. (canceled)
